Nxera Pharma Co., Ltd.

Industry

  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Vaccines
  • Biotechnology

Other Names/Subsidiaries

  • Heptares Therapeutics Limited
  • Heptares Zurich
  • G7 Therapeutics
  • NewCo
  • Sosei Co., Ltd
  • Sosei Heptares
See more in Biomedtracker

Latest on Nxera Pharma Co., Ltd.

Scrip

Asia Deal Watch: Daiichi Sankyo Teams With Nosis On Extrahepatic RNA Therapies

 
• By Joseph Haas, Jung Won Shin, and Lisa Takagi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Start-Up Nosis Partners Its AI Pl

Scrip

Idorsia On The Edge Again As Aprocitentan Deal Stalls

 
• By Kevin Grogan

Idorsia’s hopes of signing a global licensing deal for its hypertension drug Tryvio before the end of the year have been dashed, leaving the cash-strapped Swiss biotech to weigh up “all strategic opti

Scrip

Asia Deal Watch: Apollo Takes A Shine To Chinese Biotech’s Cardiometabolic Candidate

 
• By Joseph Haas, Lisa Takagi, Dexter Jie Yan, and Jung Won Shin

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Apollo Licenses Ex-China Rights T

Pink Sheet

Mecobalamin For ALS Among New Japan Recommendations

 
• By Lisa Takagi

An advisory committee to Japan’s Ministry of Health, Labour and Welfare (MHLW) has recommended the approval of eight new drugs, including a global-first indication for Eisai Co., Ltd. ’s ultra-high d